LIVOSTIN OPHTHALMIC SUSPENSION

AU:B3 R01AC02(WHO)S01GX02(WHO) US:℞-onlyIn general: ℞ (Prescription only) (3S,4R)-1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid 79516-68-0Y 54385 1586 DB01106Y 16736421Y H68BP06S81 D08117Y ChEMBL1201312N DTXSID1048548 Interactive image Fc1ccc(cc1)[C@]2(CC[C@@H](CC2)N3CC[C@@]([C@H](C)C3)(c4ccccc4)C(O)=O)C#N InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1YKey:ZCGOMHNNNFPNMX-KYTRFIICSA-NY Levocabastine(trade nameLivostinor Livocab, depending on the region) is a selective second-generationH1receptor antagonistwhich was discovered atJanssen Pharmaceuticain 1979. It is used for allergicconjunctivitis. As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for theneurotensinreceptorNTS2, and was the first drug used to characterise the different neurotensin subtypes.This has made it a useful tool for the study of this receptor. Thepharmaceutical drugBilinais a combination of Levocabastine,benzalkonium chloride, and other components and is typically used in a 0.5 mg/ml suspension as eye-drops, dispensed in 4ml bottles for the treatment of allergicconjunctivitisor similar allergic ocular conditions. Another formulation is available as anasal sprayfor the management ofallergic rhinitis.